LYNDA HEAPHY: Open Payments
NPI 1952309387 · SURPRISE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,030 in 46 payments from 19 companies in 2025. Trend: 2023 $3,601 · 2024 $3,857 · 2025 $1,030
Food & beverage: $1,030
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 7 | $195 |
| GlaxoSmithKline, LLC. | 8 | $149 |
| AstraZeneca Pharmaceuticals LP | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 2 | $69 |
| Actelion Pharmaceuticals US, Inc. | 2 | $57 |
| Insmed, Inc. | 2 | $57 |
| Merck Sharp & Dohme LLC | 2 | $54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $47 |
| Viatris Specialty LLC | 2 | $45 |
| United Therapeutics Corporation | 2 | $44 |
Products named: DUPIXENT, TRELEGY ELLIPTA, Arikayce, NUCALA, IMFINZI, OFEV, YUPELRI, remede System.
Industry payments across AZ — which companies pay providers there.
